{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/insulin-therapy-in-type-1-diabetes/how-up-to-date-is-this-topic/update/","result":{"pageContext":{"chapter":{"id":"d93b8dec-544f-532d-902d-66e613ea505d","slug":"update","fullItemName":"Update","depth":2,"htmlHeader":"<!-- begin field 6f6c0c67-fd8c-4cc1-bca7-106046b0ba30 --><h2>Update</h2><!-- end field 6f6c0c67-fd8c-4cc1-bca7-106046b0ba30 -->","summary":null,"htmlStringContent":"<!-- begin item 4002410c-a694-4876-8144-0dce191994b8 --><!-- end item 4002410c-a694-4876-8144-0dce191994b8 -->","topic":{"id":"418fc016-0e56-5e3b-b2ea-3927d2911520","topicId":"fea45be3-7039-4e82-a497-8f104e2219fa","topicName":"Insulin therapy in type 1 diabetes","slug":"insulin-therapy-in-type-1-diabetes","lastRevised":"Last revised in July 2020","chapters":[{"id":"954264ab-b538-5bf1-97b7-0f924f8d8cf8","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"3ff43781-7d14-5b7f-afad-bdf21a03a066","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"2847fe29-3881-5cdb-a7bc-46613048cf07","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"cca9cb48-98c0-532b-be68-7babcbefb124","slug":"changes","fullItemName":"Changes"},{"id":"d93b8dec-544f-532d-902d-66e613ea505d","slug":"update","fullItemName":"Update"}]},{"id":"ec62a12c-2df5-5ba3-83ae-04575a5df833","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"bea46ae9-5b5d-5501-8642-95bebd864aa1","slug":"goals","fullItemName":"Goals"},{"id":"637cdedd-d944-52d1-9428-f71dedd59179","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"ecc1db03-98d4-5682-a7a3-7d52d3da9b84","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"ef866cac-6d08-5a10-a858-cbbf60d218e6","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"2dc6198c-0433-5023-aa1b-6862a4d3ed59","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"a289174b-e042-5fce-924a-1f34b54849a9","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"bad524b5-e1b5-52b0-aa55-2cc89cb11660","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"457536b7-af83-548a-b54e-8d0edaeafd3f","slug":"what-is-insulin","fullItemName":"What is insulin?"}]},{"id":"e457b08c-e5c6-5790-ba8c-f88e071da0b0","fullItemName":"Management","slug":"management","subChapters":[{"id":"676c7992-874b-537d-8c19-1f2960b3cc32","slug":"insulin-therapy-type-1-diabetes","fullItemName":"Scenario: Insulin therapy - type 1 diabetes"}]},{"id":"4beb3cd5-7f83-5f1c-9623-cc5e61eae703","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"5da0d096-2a12-5776-bc2b-bd37233342e8","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"8863b2a8-ba84-522f-8b51-20da713ec903","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"b16eeb02-30c3-54db-ad00-8543e4b4cef6","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"452ae6ee-2e11-57b1-bbed-4515efd11fc8","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"ead30a9a-3f18-5514-8a77-69d9bf069d3c","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"6d600b94-edf3-51e4-85d9-72002fbf5fc5","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"6648325a-6d11-5ed7-9bb9-aff9e9d4ee55","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"2847fe29-3881-5cdb-a7bc-46613048cf07","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"172b82b6-f50c-500d-918e-d4bf0e324f13","slug":"new-evidence","fullItemName":"New evidence","depth":3,"htmlHeader":"<!-- begin field c078b8de-ccbe-4216-93e6-358a9382863d --><h3>New evidence</h3><!-- end field c078b8de-ccbe-4216-93e6-358a9382863d -->","summary":null,"htmlStringContent":"<!-- begin item 036ca8f4-147a-4093-af13-010781418054 --><!-- begin field 74bc80e3-b283-4981-b039-9ef122bd9872 --><h3>Evidence-based guidelines</h3><!-- end field 74bc80e3-b283-4981-b039-9ef122bd9872 --><!-- begin field 6ec1b75f-e58a-468c-9752-05a2dc86d8cc --><p>No new evidence-based guidelines since 1 July 2020.</p><!-- end field 6ec1b75f-e58a-468c-9752-05a2dc86d8cc --><!-- begin field 2caa9ef3-5f0b-4511-b8f3-5c3ccf46d350 --><h3>HTAs (Health Technology Assessments)</h3><!-- end field 2caa9ef3-5f0b-4511-b8f3-5c3ccf46d350 --><!-- begin field 0ef66332-af3e-4cfc-9309-89952f80afbf --><p>No new HTAs since 1 July 2020.</p><!-- end field 0ef66332-af3e-4cfc-9309-89952f80afbf --><!-- begin field 20fbba49-4866-4f7c-b762-744eb9b340ce --><h3>Economic appraisals</h3><!-- end field 20fbba49-4866-4f7c-b762-744eb9b340ce --><!-- begin field 709f8bf1-07a3-44a3-8152-998c5d3f07c0 --><p>No new economic appraisals relevant to England since 1 July 2020.</p><!-- end field 709f8bf1-07a3-44a3-8152-998c5d3f07c0 --><!-- begin field 5889385f-138b-4bd5-bac3-92eb1a7785c9 --><h3>Systematic reviews and meta-analyses</h3><!-- end field 5889385f-138b-4bd5-bac3-92eb1a7785c9 --><!-- begin field 083e9c67-186d-4636-8bd7-1adbd59a82d2 --><p>No new systematic reviews and meta-analyses published since 1 July 2020.</p><!-- end field 083e9c67-186d-4636-8bd7-1adbd59a82d2 --><!-- begin field 02da2cc3-b15d-4c80-a630-41ecd63fe8c7 --><h3>Primary evidence</h3><!-- end field 02da2cc3-b15d-4c80-a630-41ecd63fe8c7 --><!-- begin field 1e6eaee0-5ee9-4265-9fac-c360bc77d2ad --><p>No new randomized controlled trials published in the major journals since 1 July 2020.</p><!-- end field 1e6eaee0-5ee9-4265-9fac-c360bc77d2ad --><!-- end item 036ca8f4-147a-4093-af13-010781418054 -->","subChapters":[]},{"id":"622aa19b-2e29-53f2-bb12-56c635dd63cf","slug":"new-policies","fullItemName":"New policies","depth":3,"htmlHeader":"<!-- begin field 700df61f-2a6d-4dc6-ac1e-436dfce57316 --><h3>New policies</h3><!-- end field 700df61f-2a6d-4dc6-ac1e-436dfce57316 -->","summary":null,"htmlStringContent":"<!-- begin item dab4fbe2-ebdc-4c3c-b7b8-bd97284614bf --><!-- begin field 4be28ec5-7ed7-4e50-a46d-7320ea90264c --><p>No new national policies or guidelines since 1 July 2020.</p><!-- end field 4be28ec5-7ed7-4e50-a46d-7320ea90264c --><!-- end item dab4fbe2-ebdc-4c3c-b7b8-bd97284614bf -->","subChapters":[]},{"id":"396d01b1-ea16-5600-b765-9d351d6226a1","slug":"new-safety-alerts","fullItemName":"New safety alerts","depth":3,"htmlHeader":"<!-- begin field 4e4ef173-0a0e-461c-b926-0d3780f1ad08 --><h3>New safety alerts</h3><!-- end field 4e4ef173-0a0e-461c-b926-0d3780f1ad08 -->","summary":null,"htmlStringContent":"<!-- begin item 8edf738b-97de-464f-8de1-14e6cfb50bdb --><!-- begin field e7229fe8-a0dc-4e08-9e5f-1eb422a4c999 --><p>No new safety alerts since 1 July 2020. </p><!-- end field e7229fe8-a0dc-4e08-9e5f-1eb422a4c999 --><!-- end item 8edf738b-97de-464f-8de1-14e6cfb50bdb -->","subChapters":[]},{"id":"66c5deb0-9fa2-57c1-98be-80e6a49620d2","slug":"changes-in-product-availability","fullItemName":"Changes in product availability","depth":3,"htmlHeader":"<!-- begin field 74b48c95-a4e0-4eca-b59a-edcc52188c98 --><h3>Changes in product availability</h3><!-- end field 74b48c95-a4e0-4eca-b59a-edcc52188c98 -->","summary":null,"htmlStringContent":"<!-- begin item 4238b6db-7310-4686-be87-97ffbb23b7c7 --><!-- begin field 42b52347-25e3-4b4b-b397-d914b46e90ff --><ul><li>Ogluo is a hybrid of GlucaGen/GlucaGen Hypokit but is available as a ready-to-use formulation intended for subcutaneous injection and indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. See more <a href=\"https://www.ema.europa.eu/en/medicines/human/summaries-opinion/ogluo\" target=\"_blank\" rel=\"noopener\" data-hyperlink-id=\"89505423-825f-4395-97c2-ac9500b5bd3e\">here</a>.</li><li>Kixelle has comparable quality, safety, and efficacy to the reference product NovoRapid and is indicated for treatment of diabetes mellitus in adults, adolescents, and children aged 1 year and above. See more <a href=\"https://www.ema.europa.eu/en/medicines/human/summaries-opinion/kixelle\" target=\"_blank\" rel=\"noopener\" data-hyperlink-id=\"6c25744a-bda3-4ee2-96c6-ac9500b64c6c\">here</a>.</li></ul><!-- end field 42b52347-25e3-4b4b-b397-d914b46e90ff --><!-- end item 4238b6db-7310-4686-be87-97ffbb23b7c7 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}